WO2005056520A8 - Composes actifs du sous-type 1 de recepteur de somatostatine (sstr1) et leur utilisation en therapie - Google Patents

Composes actifs du sous-type 1 de recepteur de somatostatine (sstr1) et leur utilisation en therapie

Info

Publication number
WO2005056520A8
WO2005056520A8 PCT/FI2004/000750 FI2004000750W WO2005056520A8 WO 2005056520 A8 WO2005056520 A8 WO 2005056520A8 FI 2004000750 W FI2004000750 W FI 2004000750W WO 2005056520 A8 WO2005056520 A8 WO 2005056520A8
Authority
WO
WIPO (PCT)
Prior art keywords
sstr1
active compounds
receptor subtype
somatostatin receptor
therapy
Prior art date
Application number
PCT/FI2004/000750
Other languages
English (en)
Other versions
WO2005056520A1 (fr
Inventor
Pia Knuuttila
Harri Salo
Jussi Tomperi
Siegfried Wurster
Anna-Marja Hoffren
Original Assignee
Juvantia Pharma Ltd Oy
Pia Knuuttila
Harri Salo
Jussi Tomperi
Siegfried Wurster
Anna-Marja Hoffren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20031824A external-priority patent/FI20031824A0/fi
Application filed by Juvantia Pharma Ltd Oy, Pia Knuuttila, Harri Salo, Jussi Tomperi, Siegfried Wurster, Anna-Marja Hoffren filed Critical Juvantia Pharma Ltd Oy
Priority to JP2006543564A priority Critical patent/JP2007513928A/ja
Priority to EP04805145A priority patent/EP1692099A1/fr
Priority to CA002547863A priority patent/CA2547863A1/fr
Publication of WO2005056520A1 publication Critical patent/WO2005056520A1/fr
Publication of WO2005056520A8 publication Critical patent/WO2005056520A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un groupe de composés actifs du sous-type 1 de récepteur de somatostatine (SSTR1) et des compositions pharmaceutiques renfermant les composés en question. L'invention concerne également l'utilisation de ces composés pour le traitement ou la prévention des maladies qui réagissent aux composés actifs SSTR1 considérés. L'invention concerne également des procédés de ciblage de tissu porteur de SSTR1, soit pour l'imagerie de tissus soit pour le transport de médicaments vers les tissus.
PCT/FI2004/000750 2003-12-12 2004-12-09 Composes actifs du sous-type 1 de recepteur de somatostatine (sstr1) et leur utilisation en therapie WO2005056520A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2006543564A JP2007513928A (ja) 2003-12-12 2004-12-09 ソマトスタチン受容体サブタイプ１（ｓｓｔｒ１）活性化合物及び治療におけるその使用
EP04805145A EP1692099A1 (fr) 2003-12-12 2004-12-09 Composes actifs du sous-type 1 de recepteur de somatostatine (sstr1) et leur utilisation en therapie
CA002547863A CA2547863A1 (fr) 2003-12-12 2004-12-09 Composes actifs du sous-type 1 de recepteur de somatostatine (sstr1) et leur utilisation en therapie

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50907303P 2003-12-12 2003-12-12
FI20031824 2003-12-12
US60/509,073 2003-12-12
FI20031824A FI20031824A0 (fi) 2003-12-12 2003-12-12 Uusia yhdisteitä ja niiden käyttö terapiassa

Publications (2)

Publication Number Publication Date
WO2005056520A1 WO2005056520A1 (fr) 2005-06-23
WO2005056520A8 true WO2005056520A8 (fr) 2005-09-15

Family

ID=34680375

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2004/000750 WO2005056520A1 (fr) 2003-12-12 2004-12-09 Composes actifs du sous-type 1 de recepteur de somatostatine (sstr1) et leur utilisation en therapie

Country Status (4)

Country Link
EP (1) EP1692099A1 (fr)
JP (1) JP2007513928A (fr)
CA (1) CA2547863A1 (fr)
WO (1) WO2005056520A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2498798C2 (ru) 2008-01-09 2013-11-20 Моликьюлар Инсайт Фармасьютикалз, Инк. Ингибиторы карбоангидразы iх
JP2011522813A (ja) * 2008-06-04 2011-08-04 アストラゼネカ アクチボラグ 低分子レプチン受容体修飾因子
EP2389361B1 (fr) 2008-12-05 2016-08-24 Molecular Insight Pharmaceuticals, Inc. Complexes de technétium et de rhénium bis (hétéroaryle) et procédés d'utilisation de ceux-ci pour inhiber le psma
WO2010065899A2 (fr) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Complexes de technétium- et rhénium-bis (hétéroaryles) et leurs procédés d'utilisation
WO2010065906A2 (fr) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Produits radiopharmaceutiques spécifiques de ca-ix pour le traitement et l'imagerie de cancer
BR112012000209B8 (pt) 2009-06-15 2021-07-27 Molecular Insight Pharm Inc heterodímeros de ácido glutâmico e seus processos de preparação
CA2860504A1 (fr) 2012-01-06 2013-07-11 Molecular Insight Pharmaceuticals Complexe metalliques de poly (carboxyl) amine contenant des ligands ayant une affinite pour l'anhydrase carbonique ix
US9447121B2 (en) 2013-01-14 2016-09-20 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2325741C (fr) * 1998-03-26 2007-05-08 Santen Pharmaceutical Co., Ltd. Nouveaux derives d'uree ayant un effet inhibitoire sur la production de tnf-.alpha.
JP4099065B2 (ja) * 2001-01-12 2008-06-11 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス 血管増殖を阻害する医薬組成物とその使用の方法
US7019109B2 (en) * 2001-03-16 2006-03-28 The Salk Institute For Bilogical Studies SSTR1-selective analogs

Also Published As

Publication number Publication date
CA2547863A1 (fr) 2005-06-23
WO2005056520A1 (fr) 2005-06-23
JP2007513928A (ja) 2007-05-31
EP1692099A1 (fr) 2006-08-23

Similar Documents

Publication Publication Date Title
WO2003096990A3 (fr) Cages proteiques pour l'administration d'agents therapeutiques et d'imagerie medicale
CA3094580C (fr) Formulations orales d'analogues de cytidine et leurs procedes d'utilisation
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
MY143795A (en) Tetrahydropyridoindole derivatives
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
WO2004112711A3 (fr) Composition orale a liberation prolongee
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
WO2002070438A3 (fr) Compositions permettant l'administration de biophosphonates
WO2007119177A3 (fr) Formulations à libération modifiée et méthodes de traitement de maladie intestinale inflammatoire
WO2007137071A3 (fr) Compositions de r(+) et s(-) pramipéxole et procédés d'utilisation de celles-ci
WO2008097924A3 (fr) Compositions pharmaceutiques comprenant des analogues du dextrométhorphane pour le traitement de troubles neurologiques
GB0623258D0 (en) Thiadiazole derivatives for the treatment of neuro-degenerative diseases
WO2006115770A3 (fr) Preparations pharmaceutiques d'olazanpine en comprimes a desintegration orale
WO2008008882A3 (fr) Modulateur du récepteur des glucocorticoïdes et procédés d'utilisation
WO2007081486A3 (fr) Administration orale de defensines pour traiter des maladies intestinales
GB2446341A (en) Method and system for transdermal drug delivery
WO2005056520A8 (fr) Composes actifs du sous-type 1 de recepteur de somatostatine (sstr1) et leur utilisation en therapie
WO2006002846A3 (fr) Nouveaux analogues de nitrobenzylthioinosine
SI1699468T1 (sl) Farmacevtski sestavek, ki obsega kompleks cink-hialuronan, za zdravljenje multiple skleroze
WO2004081031A3 (fr) Fixation de medicament a mediation de thiol a des peptides de ciblage
HK1075390A1 (en) Citalopram for the treatment of elevated blood pressure
WO2004073627A3 (fr) Methode et compositions therapeutiques pour administration topique
WO2008014888A3 (fr) Dérivé de imino-imidazo-pyridine présentant une activité antithrombotique
EP1752147A4 (fr) Médicament pour la prévention ou le traitement du diabète
WO2004078761A8 (fr) Cilazapril de purete enantiomerique et procede pour sa preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2547863

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004805145

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006543564

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004805145

Country of ref document: EP